Articles By Wayne Koberstein, Executive Editor

Industry’s Reflected Gold
Industry’s Reflected Gold In my travels, I’ve especially noted three areas of unavoidable transformation due to forces quite beyond the industry’s control: women’s advocacy, the drug-pricing stalemate, and the new politics.  Continue Reading...
  • Industry Explorers Blaze On: Pat Andrews
    Industry Explorers Blaze On: Pat Andrews

    A look at the 26-year career of Pat Andrews, CEO of Boston Biomedical, who went from Big Pharma to small biotech.

  • Not a Bad Year, After All
    Not a Bad Year, After All

    Peter Meath, who heads the Life Science Group at J.P. Morgan’s Commercial Banking business, offers advice to novice entrepreneurs for turning a company’s novel science into a viable business.

  • Companies To Watch: Daré Bioscience
    Companies To Watch: Daré Bioscience

    Bridging to commercialization of women’s reproductive health products — starting with a novel contraceptive.

  • More from the Women of Biopharma — Full Measures of Progress
    More from the Women of Biopharma — Full Measures of Progress

    In the December 2017 issue’s article, “The Women of Biopharma — Will They Gain or Lose Ground in 2018?” we summarize the responses of those who chose to contribute as panelists in a “virtual roundtable” discussion. Here, as promised, we are posting their written responses in full.

  • The Women Of Biopharma — Will They Gain Or Lose Ground In 2018?
    The Women Of Biopharma — Will They Gain Or Lose Ground In 2018?

    We hear from 11 women and one man in biopharma. Although we were not aiming for “balance” here — there are plenty of opposing opinions out there already — the sole gender-exception in this group supplies another valuable viewpoint…

  • Companies To Watch: Abivax
    Companies To Watch: Abivax

    With 24 employees, Paris-based Abivax is in Phase 2 clinical development of its lead drug candidate, which is a potential functional cure for HIV infection.  It has also recently spawned an early clinical program in inflammatory bowel disease (IBD).

  • Industry Explorers Blaze On: Deborah Dunsire
    Industry Explorers Blaze On: Deborah Dunsire

    Deborah Dunsire has lived and worked in a world driven by commercial drug development for three decades. She’s worked for Big Pharmas such as Novartis and Sandoz and is now trying her hand at managing a small pharma as president & CEO of XTuit. For sure, she’s been a pioneer — but she’s not done yet.

  • Companies To Watch: Madrigal Pharmaceuticals
    Companies To Watch: Madrigal Pharmaceuticals

    Madrigal Pharmaceuticals is taking on NASH and other liver diseases by targeting the thyroid hormone beta receptor. The company expects to begin seeing top line Phase 2 trial results in late 2017, with more released in 2018.

  • Prometic: New Tech Harvests Orphan Treatments
    Prometic: New Tech Harvests Orphan Treatments

    Always stick with your original goals, even when you reap another, off-the-scale success. Like many biopharma companies, Prometic invented a novel technology platform, initially to make new medicines available to unserved populations.

  • Cytokinetics: Keeping Its Sights On Independence
    Cytokinetics: Keeping Its Sights On Independence

    Can a biopharma company have a soul? If so, the soul should be one that endures. “The biology is the soul of our company,” says Robert Blum, president and CEO of Cytokinetics. “We have pioneered an area of biology — muscle activation — proven to offer a compelling pharmacology.

  • Companies To Watch: Arena Pharmaceuticals
    Companies To Watch: Arena Pharmaceuticals

    By early 2016, Arena’s board decided to remake the company, beginning with new management and a new strategy. Since then, the company has evolved back to a core drug development platform.

  • The Mechanics Of Hyperbole
    The Mechanics Of Hyperbole

    Oncology isn’t the only therapeutic area subject to the hyperbole of hope. It is just the most perfect example of hype, an all-too-common state of mind in the “cancer community.

  • Ipsen In The USA — Building & Leading The Subsidiary As Startup
    Ipsen In The USA — Building & Leading The Subsidiary As Startup

    Cynthia Schwalm, president, North American commercial operations for Ipsen, gives the backstory of what happened when this company decided to change its approach to the U.S. market.

  • Companies To Watch: ProMIS Neurosciences
    Companies To Watch: ProMIS Neurosciences

    ProMIS Neurosciences believes inaccurate targeting of mAbs is to blame, in fact, for lack of progress against Alzheimer’s disease.

More From Wayne Koberstein
Wayne Koberstein

Wayne Koberstein


Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.